MASI Stock Recent News
MASI LATEST HEADLINES
Masimo has allowed founder Joe Kiani to pledge more than half his $660 million stake in the company as collateral for personal loans.
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Masimo's (MASI) R&D activities raise optimism about the stock.
Masimo's (MASI) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
Here is how Masimo (MASI) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Joe Kiani, Masimo CEO, joins 'Closing Bell: Overtime' to discuss the company spinning off its consumer business.
Quentin Koffey's Politan Capital waged a successful proxy fight at Masimo last year, and it is now seeking two more board seats.
Masimo Corp.'s stock MASI, +1.40% was up 12% in premarket trading on Monday after The Wall Street Journal reported that activist investor Politan Capital Management plans to nominate two more members to the patient-monitoring technology company's board. Politan Capital, which was launched by Quentin Koffey, already has two seats on the company's board.